{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T13:12:49Z","timestamp":1760015569008,"version":"3.40.4"},"reference-count":18,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2014,6,12]],"date-time":"2014-06-12T00:00:00Z","timestamp":1402531200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatric Dermatology"],"published-print":{"date-parts":[[2014,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Imatinib mesylate was the first of several tyrosine kinase inhibitors approved for use in the treatment of a number of human cancers. Adverse cutaneous reactions to imatinib are common. Pseudoporphyria has been infrequently reported in adults undergoing imatinib therapy for chronic myeloid leukemia. We present two children with pseudoporphyria induced by imatinib therapy for hematologic malignancies. In view of the burgeoning use of imatinib in children, physicians should be aware that pseudoporphyria may develop as a consequence of imatinib therapy.<\/jats:p>","DOI":"10.1111\/pde.12380","type":"journal-article","created":{"date-parts":[[2014,6,12]],"date-time":"2014-06-12T06:47:43Z","timestamp":1402555663000},"page":"603-607","source":"Crossref","is-referenced-by-count":9,"title":["Imatinib Mesylate\u2013Induced Pseudoporphyria in Two Children"],"prefix":"10.1111","volume":"31","author":[{"given":"Caroline","family":"Mahon","sequence":"first","affiliation":[{"name":"Department of Paediatric Dermatology Starship Children's Health Auckland New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Purvis","sequence":"additional","affiliation":[{"name":"Department of Paediatric Dermatology Starship Children's Health Auckland New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Laughton","sequence":"additional","affiliation":[{"name":"Department of Paediatric Haematology and Oncology Starship Children's Health Auckland New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Bradbeer","sequence":"additional","affiliation":[{"name":"Department of Paediatric Haematology and Oncology Starship Children's Health Auckland New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lochie","family":"Teague","sequence":"additional","affiliation":[{"name":"Department of Paediatric Haematology and Oncology Starship Children's Health Auckland New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,6,12]]},"reference":[{"key":"e_1_2_4_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra013339"},{"key":"e_1_2_4_3_1","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0022-3565(24)38879-2","article-title":"Abl protein tyrosine kinase inhibitor ST1571 inhibits in vitro signal transduction mediated by c\u2010Kit and platelet\u2010derived growth factor receptors","volume":"295","author":"Buchdinger E","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_4_4_1","first-page":"413","article-title":"Longer follow\u2010up confirms major improvement in outcome in children and adolescents with Philadelphia chromosome acute lymphoblastic leukaemia treated with continuous imatinib and hematopoietic stem cell transplantation. Results from the Spanish Cooperative Study SHOP\/ALL\u20102005","volume":"162","author":"Rivers S","year":"2013","journal-title":"Br J Haematol"},{"key":"e_1_2_4_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.01.001"},{"key":"e_1_2_4_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.04.034"},{"key":"e_1_2_4_7_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.143974"},{"key":"e_1_2_4_8_1","doi-asserted-by":"publisher","DOI":"10.5455\/apr.011620131348"},{"key":"e_1_2_4_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12172"},{"key":"e_1_2_4_10_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04151_4.x"},{"key":"e_1_2_4_11_1","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2003.44"},{"key":"e_1_2_4_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6600893"},{"key":"e_1_2_4_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.2008.02985.x"},{"key":"e_1_2_4_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2009.03456.x"},{"key":"e_1_2_4_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2010.01.060"},{"key":"e_1_2_4_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.2011.04289.x"},{"key":"e_1_2_4_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2012.05574.x"},{"key":"e_1_2_4_18_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar2117"},{"key":"e_1_2_4_19_1","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2000.111338"}],"container-title":["Pediatric Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fpde.12380","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/pde.12380","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T09:39:54Z","timestamp":1746265194000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/pde.12380"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6,12]]},"references-count":18,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["10.1111\/pde.12380"],"URL":"https:\/\/doi.org\/10.1111\/pde.12380","archive":["Portico"],"relation":{},"ISSN":["0736-8046","1525-1470"],"issn-type":[{"type":"print","value":"0736-8046"},{"type":"electronic","value":"1525-1470"}],"subject":[],"published":{"date-parts":[[2014,6,12]]}}}